Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VRCA 
Verrica Pharmaceuticals Inc (VRCA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: VRCA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4
1 Year Target Price $4
| 2 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.67% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.03M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 5 | Beta 1.76 | 52 Weeks Range 0.38 - 8.98 | Updated Date 06/30/2025 |
52 Weeks Range 0.38 - 8.98 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -236.41% |
Management Effectiveness
Return on Assets (TTM) -62.87% | Return on Equity (TTM) -1546.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 61867475 | Price to Sales(TTM) 6.83 |
Enterprise Value 61867475 | Price to Sales(TTM) 6.83 | ||
Enterprise Value to Revenue 8.62 | Enterprise Value to EBITDA -11.7 | Shares Outstanding 92491000 | Shares Floating 17281017 |
Shares Outstanding 92491000 | Shares Floating 17281017 | ||
Percent Insiders 44.37 | Percent Institutions 31.9 |
Analyst Ratings
Rating 3 | Target Price 4 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Verrica Pharmaceuticals Inc
Company Overview
History and Background
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing and commercializing novel treatments for viral skin diseases. Founded in 2013, Verrica has focused on addressing unmet needs in dermatology, particularly in the treatment of common viral skin infections like molluscum contagiosum.
Core Business Areas
- Dermatology Therapeutics: Focuses on developing and commercializing treatments for viral skin diseases.
Leadership and Structure
The leadership team includes key executives in areas such as research and development, commercial operations, and finance. The organizational structure is typical of a biotech company, with functional departments responsible for specific areas of operation.
Top Products and Market Share
Key Offerings
- YCANTH (cantharidin) topical solution: YCANTH is Verrica's FDA-approved product for the treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. Securing reimbursement has been a key challenge. Competitors in this space include compounded cantharidin products (without FDA approval) and alternative destruction methods like cryotherapy.
Market Dynamics
Industry Overview
The dermatology therapeutics market is growing due to increasing awareness of skin diseases and the development of new treatments. Viral skin infections represent a significant area of unmet need.
Positioning
Verrica is positioned as a company focused on innovative dermatology treatments, particularly for viral skin diseases. Its competitive advantage lies in its FDA-approved product, YCANTH.
Total Addressable Market (TAM)
The molluscum contagiosum market is estimated to be in the hundreds of millions of dollars annually. Verrica is aiming to capture a significant share of this market with YCANTH.
Upturn SWOT Analysis
Strengths
- FDA-approved product (YCANTH)
- Focus on underserved market (viral skin diseases)
- Experienced management team
Weaknesses
- Single product dependency
- Reimbursement challenges
- Limited commercial infrastructure
Opportunities
- Expansion into new indications
- Partnerships with larger pharmaceutical companies
- Geographic expansion
Threats
- Competition from established dermatology companies
- Generic entry
- Regulatory changes
Competitors and Market Share
Key Competitors
- DERM
- MARA
- VRX
Competitive Landscape
Verrica faces competition from established dermatology companies. Its advantage lies in its focus on viral skin diseases and its FDA-approved product. However, it faces challenges related to reimbursement and commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Verrica's growth has been tied to the development and commercialization of YCANTH.
Future Projections: Future growth depends on the successful commercialization of YCANTH, expansion into new markets, and potential pipeline development.
Recent Initiatives: Recent initiatives include efforts to secure reimbursement for YCANTH and expand its use in clinical practice.
Summary
Verrica Pharmaceuticals is a dermatology company with a focus on viral skin diseases, primarily molluscum contagiosum. The company's future hinges on the successful commercialization of YCANTH, the company's only FDA-approved product. Verrica faces challenges related to reimbursement and competition. Diversification of its product pipeline would mitigate risks associated with single-product dependency.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Industry reports, Press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Verrica Pharmaceuticals Inc
Exchange NASDAQ | Headquaters West Chester, PA, United States | ||
IPO Launch date 2018-06-15 | President, CEO & Director Dr. Jayson M. Rieger M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 71 | Website https://www.verrica.com |
Full time employees 71 | Website https://www.verrica.com | ||
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.